DermTech

Traded on the St. Petersburg Stock Exchange
DermTech is an American molecular diagnostic company that develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions. The company sells its products primarily to pathology and oncology practitioners. It is headquartered in La Jolla, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

DermTech balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

DermTech cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

DermTech multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

DermTech profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
DermTech assets
DermTech cash flows

DermTech dividend policy

The company doesn't provide dividends
DermTech news
04.05.2022
The loss of DermTech under GAAP for the 3 months of 2022 was $30.108 million, doubling from $15.068 million in the previous year. Revenue increased 47.3% to $3.718 billion compared to $2.524 billion a year earlier.
Source: {source} pictogram investors.dermtech.com
Pictogram next
02.03.2022
DermTech's GAAP loss for 2021 was $78.335 million, up 2.1 times from $36.477 million in the previous year. Revenue doubled to $11.838 million from $5.885 million a year earlier.
Source: {source} pictogram investors.dermtech.com
Pictogram next
10.11.2021
DermTech's GAAP loss for 9M 2021 was $52.282 million, doubling from $25.775 million in the previous year. Revenue increased 2.3 times to $8.673 million from $3.764 million a year earlier.
Source: {source} pictogram investors.dermtech.com
Pictogram next
05.08.2021
DermTech's GAAP loss for 6 months 2021 was $32.17 million, up 95% from $16.494 million in the previous year. Revenue increased 2.35 times to $5.643 million from $2.401 million a year earlier.
Source: {source} pictogram investors.dermtech.com
Pictogram next
All DermTech news
General information
Company nameDermTech
Tags#cancer treatment
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address11099 North Torrey Pines Road Suite 100 La Jolla, CA 92037 United States
Mailing address11099 North Torrey Pines Road Suite 100 La Jolla, CA 92037 United States
Websiteinvestors.dermtech.com
Information disclosurewww.sec.gov